Clinical trials: Lymphoproliferative Disorders
Multiple Myeloma
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
The purpose of this study is to determine the best dose of ACY-1215 in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
- Trial name
- NCT01583283
- Testing
- ACY-1215, lenalidomide, Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Celgene
Multiple Myeloma
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
A Phase 1/2, Open Label Study of SL-401 in Combination with Pomalidomide and Dexamethasone In Relapsed and Refractory Multiple Myeloma
- Trial name
- NCT02661022
- Testing
- SL-401 7 µg/kg/day, SL-401 9 µg/kg/day
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Stemline Therapeutics, Inc.
Acute Lymphoblastic Leukemia, Acute Leukemias
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Leukemias, Acute Myeloid Leukemia
- Trial name
- NCT07295951
- Testing
- 14C-bleximenib, bleximenib
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Phase 1(a \& b): To evaluate the side effects and determine the best dose of oral ACY-1215 as monotherapy, and also in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple…
- Trial name
- ACY-1215 (NCT01323751)
- Testing
- ACY-1215
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Celgene
Multiple Myeloma
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
The purpose of this study is to compare the efficacy of lenalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of lenalidomide and low dose dexamethasone without pembrolizumab in terms of progression-free…
- Trial name
- NCT02579863
- Testing
- Pembrolizumab, Lenalidomide, Dexamethasone
- Volunteers
- 310 people
- Sponsor
- Merck Sharp & Dohme LLC
Neuroblastoma, Rhabdomyosarcoma
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
This is a Phase I, open-label, dose-escalation trial of JX-594 (Pexa-Vec) in pediatric patients with advanced/metastatic, unresectable solid tumors refractory to standard therapy and/or the patient does not tolerate standard…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Wilm's Tumor
- Trial name
- NCT01169584
- Testing
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Jennerex Biotherapeutics
Lymphoma, Large B-Cell, Diffuse
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells.
- Trial name
- NCT06890884
- Testing
- Zilovertamab vedotin, Rituximab, Cyclophosphamide
- Where
- 147 sites in United States, Belgium and 7 more
- Volunteers
- 594 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects with relapsed and refractory multiple myeloma.
- Trial name
- NCT00511238
- Testing
- carfilzomib
- Where
- 34 sites in United States, Canada
- Volunteers
- 312 people
- Sponsor
- Amgen
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
A Phase I/IIa, open-label, uncontrolled study to evaluate the safety and efficacy of Astarabine (BST-236) as single agent in patients with refractory or relapsed Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)…
- Trial name
- BSTPHASE1-01 (NCT02544438)
- Testing
- Astarabine (BST-236)
- Where
- 2 sites in Israel
- Volunteers
- 20 people
- Sponsor
- BioSight Ltd.
Multiple Myeloma
Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma
The purpose of this study is to provide bortezomib to patients with multiple myeloma who have received at least 2 previous lines of therapy and are refractory or have relapse after their last treatment.
- Trial name
- NCT00440635
- Testing
- Bortezomib, tradename Velcade
- Volunteers
- 641 people
- Sponsor
- Janssen-Cilag International NV
Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
This single arm study will evaluate the safety and efficacy of MabThera maintenance therapy following a MabThera-containing induction regimen in first line or relapsed patients with follicular non-Hodgkin's lymphoma.
- Trial name
- NCT00430352
- Testing
- rituximab [MabThera/Rituxan]
- Where
- 178 sites in Albania, Argentina and 22 more
- Volunteers
- 545 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Malignancies, Malignant Lymphoma
Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma
The purpose of this study is to investigate the safety and tolerability of AZD 1208 up to a maximum tolerated dose (MTD) and define the dose(s) for further clinical evaluation when given daily to patients with advanced solid…
- Trial name
- NCT01588548
- Testing
- AZD1208
- Where
- 3 sites in Japan, United Kingdom
- Volunteers
- 43 people
- Sponsor
- AstraZeneca
Multiple Myeloma
A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma
This is a multicenter, open-label, Phase 1/2 study to determine the recommended dose and regimen of durvalumab in combination with lenalidomide (LEN) with and without dexamethasone (dex) in adults with newly diagnosed multiple…
- Trial name
- NCT02685826
- Testing
- Durvalumab, Lenalidomide, Dexamethasone
- Where
- 54 sites in United States, Canada and 6 more
- Volunteers
- 56 people
- Sponsor
- Celgene
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
This Phase I clinical trial is evaluating chimeric-antigen receptor (CAR) T-cells (CM-CS1 T cells) which recognize NKG2D-ligands on the surface of cancer cells.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT02203825
- Testing
- CM-CS1 T-cell infusion
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Celyad Oncology SA
Hematologic Malignancies, Leukemia
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
The purpose of this phase II study is to assess the efficacy of AP23573 in patients with specified relapsed or refractory hematological malignancies.
- Conditions
- Hematologic Malignancies, Leukemia, Myelodysplastic Syndromes, Myeloid Metaplasia
- Trial name
- NCT00086125
- Testing
- ridaforolimus
- Where
- 8 sites in United States
- Volunteers
- 57 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
The goal of the clinical trial is to collect safety data and information on how the body processes BVd in people with multiple myeloma (MM) who have moderate liver problems, compared with similar participants who have normal…
- Trial name
- NCT07609706
- Testing
- Belantamab mafodotin, Bortezomib, Dexamethasone
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Relapsed or Refractory Multiple Myeloma
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
This study is aimed to evaluate the safety, feasibility and efficacy of CAR-T cell therapy in the treatment of relapsed or refractory multiple myeloma
- Trial name
- NCT04626752
- Testing
- BCMA CAR-T, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Non-Hodgkin's B-cell Lymphoma
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
This is an active treatment, extended access study open solely to those subjects who have successfully completed the Core and Repeat Dosing portions of the MT-3724_NHL_001_US clinical study and who, in the investigator's…
- Trial name
- NCT02715843
- Testing
- MT-3724
- Where
- 3 sites in United States
- Sponsor
- Molecular Templates, Inc.
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
The purpose of this study is to evaluate the objective response rate (ORR) of E7777 in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT02676778
- Testing
- E7777
- Where
- 20 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eisai Co., Ltd.
Myopia, Myopia, Moderate
Software Refraction With Mobilerone Versus Retinoscopy
Software refraction in the mobilerone for myopia and astigmatism is a novel medical device for myopia adults and elder children with or without astigmatism.
- Conditions
- Myopia, Myopia, Moderate, Astigmatism
- Trial name
- SRMR (NCT06059521)
- Testing
- Software refraction with Eye Test Technology in a mobilerone, Retinoscopy
- Where
- 3 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Beijing Airdoc Technology Co., Ltd.